Breaking Down SG&A Expenses: Grifols, S.A. vs TG Therapeutics, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Grifols, S.A., a global leader in plasma-derived medicines, and TG Therapeutics, Inc., a biopharmaceutical company focused on developing treatments for B-cell diseases, present a fascinating contrast in their SG&A spending from 2014 to 2023.

Grifols, S.A.: A Steady Climb

Grifols has seen a consistent increase in SG&A expenses, growing by approximately 90% over the decade. This steady rise reflects the company's expansion and increased operational activities.

TG Therapeutics, Inc.: A Volatile Journey

In contrast, TG Therapeutics experienced a more volatile trajectory, with a significant spike in 2020 and 2021, where expenses surged by over 500% compared to 2014. This fluctuation highlights the challenges and investments required in the biotech sector.

Understanding these trends offers valuable insights into the strategic priorities and market dynamics faced by these companies.